Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

David Calverley, G. J. Roth

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

Original languageEnglish (US)
Pages (from-to)1231-1249
Number of pages19
JournalHematology/Oncology Clinics of North America
Volume12
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

clopidogrel
Ticlopidine
Integrins
Aspirin
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Percutaneous Coronary Intervention
Atherosclerosis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Antiplatelet therapy : Aspirin, ticlopidine/clopidogrel, and anti- integrin agents. / Calverley, David; Roth, G. J.

In: Hematology/Oncology Clinics of North America, Vol. 12, No. 6, 1998, p. 1231-1249.

Research output: Contribution to journalArticle

@article{2e6b9af2fc9a4f4e866c66441b7c33e0,
title = "Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents",
abstract = "Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.",
author = "David Calverley and Roth, {G. J.}",
year = "1998",
doi = "10.1016/S0889-8588(05)70051-4",
language = "English (US)",
volume = "12",
pages = "1231--1249",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

AU - Calverley, David

AU - Roth, G. J.

PY - 1998

Y1 - 1998

N2 - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

AB - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

UR - http://www.scopus.com/inward/record.url?scp=0032443790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032443790&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70051-4

DO - 10.1016/S0889-8588(05)70051-4

M3 - Article

C2 - 9922934

AN - SCOPUS:0032443790

VL - 12

SP - 1231

EP - 1249

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -